Limited batch quantity allocated for use in Pfizer Australia employee vaccination program
I would to like to draw your attention to here. This is the Therapeutic Goods Administration (TGA) of Australia’s website. A government website. In this link, you will find a page with information about the batch release assessment process for COVID-19 vaccines in Australia.
TGA Laboratories have been performing batch release and testing on all batches of COVID-19 vaccines that have been supplied in Australia. Batch release assessment is a critical part of the regulatory oversight of vaccine quality. It is especially important for vaccines that are provisionally approved, such as COVID-19 vaccines.
The information available covers all COVID-19 vaccines including the Australian manufactured AstraZeneca COVID-19 vaccine.
The table of information will be regulary updated as additional batches are assessed.
Very professional typo in the word ‘regularly’.
There is a special list of batches or VAX LOTs in the Table that have a funny little paragraph written beside them that goes like this:
Not tested. OCABR Reviewed. Limited batch quantity allocated for use in Pfizer Australia employee vaccination program.
So. Many. Questions.
Here’s the list of VAX LOTs that qualify:
None of these appear in VAERS. Why would they? Below is a screenshot of the Table where you can find these ‘special VAX LOTs’. This sure does seem supportive of my idea (that I had a year ago) that at least 1/3 of all all the Pfizer batches placebo. It would explain a lot in Israel.
If anyone has more information on this, let me know.